Distribution of BCL-6 mutations in different subsets of B-lineage diffuse large cell lymphoma (B-DLCL)
| B-DLCL Subset . | BCL-6 Mutations (positive/tested)* . |
|---|---|
| Systemic de novo B-DLCL | 33/66 (50.0%) |
| Transformed B-DLCL† | 3/5 (60.0%) |
| Primary mediastinal B-DLCL with sclerosis | 1/10 (10.0%) (P < .01) |
| CD5+ B-DLCL | 4/9 (44.4%) |
| Primary splenic B-DLCL | 9/15 (60.0%) |
| Primary extranodal B-DLCL‡ | 7/12 (58.3%) |
| CD30+ anaplastic B-DLCL | 2/5 (40.0%) |
| Primary central nervous system B-DLCL | 2/3 (66.6%) |
| B-DLCL Subset . | BCL-6 Mutations (positive/tested)* . |
|---|---|
| Systemic de novo B-DLCL | 33/66 (50.0%) |
| Transformed B-DLCL† | 3/5 (60.0%) |
| Primary mediastinal B-DLCL with sclerosis | 1/10 (10.0%) (P < .01) |
| CD5+ B-DLCL | 4/9 (44.4%) |
| Primary splenic B-DLCL | 9/15 (60.0%) |
| Primary extranodal B-DLCL‡ | 7/12 (58.3%) |
| CD30+ anaplastic B-DLCL | 2/5 (40.0%) |
| Primary central nervous system B-DLCL | 2/3 (66.6%) |
The criteria adopted for subdividing B-DLCL into distinct subsets are specified in “Materials and Methods.”
Statistically significant differences in BCL-6 mutation frequency are indicated by the corresponding P-value.
B-DLCL derived from histologic transformation of a previous follicular lymphoma.
B-DLCL presenting in extranodal sites without evidence of nodal involvement at diagnosis.